GSK3 polypeptides

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GS...

Full description

Saved in:
Bibliographic Details
Main Authors Harrison, Stephen D, Hall, John A, Calderon-Cacia, Maria, Zhong, Ziyang, Fang, Eric Y, Coit, Doris G, Nguyen, Steve H, Medina-Selby, Angelica
Format Patent
LanguageEnglish
Published 14.11.2006
Online AccessGet full text

Cover

More Information
Summary:The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.